MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $3.51 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 39,212 shares of the medical equipment provider’s stock after acquiring an additional 1,531 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Lantheus were worth $3,508,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. State of New Jersey Common Pension Fund D raised its position in Lantheus by 0.4% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock worth $2,364,000 after acquiring an additional 115 shares in the last quarter. Bleakley Financial Group LLC raised its position in Lantheus by 6.1% during the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock worth $200,000 after acquiring an additional 129 shares in the last quarter. Avantax Advisory Services Inc. raised its position in Lantheus by 5.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock worth $213,000 after acquiring an additional 132 shares in the last quarter. Foundry Partners LLC raised its position in Lantheus by 4.5% during the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider’s stock worth $278,000 after acquiring an additional 133 shares in the last quarter. Finally, UMB Bank n.a. raised its position in Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after acquiring an additional 134 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of LNTH opened at $78.25 on Tuesday. The firm has a market capitalization of $5.41 billion, a PE ratio of 13.02 and a beta of 0.23. The company’s 50-day moving average is $96.65 and its 200-day moving average is $92.87. Lantheus Holdings, Inc. has a fifty-two week low of $75.00 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The company had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Lantheus’s revenue for the quarter was up .8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.69 earnings per share. Analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 63,109 shares of company stock valued at $6,016,046 over the last ninety days. 1.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on LNTH. Truist Financial dropped their price target on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. Finally, B. Riley dropped their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Lantheus presently has a consensus rating of “Buy” and a consensus target price of $132.67.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.